Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer

Sponsor
AIO-Studien-gGmbH
Study ID
NCT03197467
Phase
PHASE2
Status
Completed

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — DRUG
    Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles

Study Details

NEOMUN is designed as an open-label, single arm, prospective, monocenter, phase II study of pembrolizumab in a neoadjuvant setting in patients with non-small cell lung cancer of Stage II/IIIA suitable for curative intent surgery.

Key Dates

Start date
Jun 18, 2018
Status verified
Apr 2025
Primary completion
Oct 30, 2021
Completion
May 5, 2023

Study Design

Enrollment
30 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pembrolizumab
    Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles

Primary Outcome Measure

Number of Patients Treated in Compliance With Protocol [ Time Frame: From screening until surgery, ca. 6-8 weeks ]

Related coverage on Hipa.ai

Related Studies